The American Society of Gene & Cell Therapy (ASGCT) is a non-profit medical and professional organization that represents researchers and scientists devoted to the discovery of new genetic and cellular therapies.
Location: United States, Wisconsin, Goerke's Corners
Phone: +1 414-278-1341
Mentions in press and media 21
Date | Title | Description |
29.08.2024 | Circio Holding ASA: First half 2024 results | Circio Holding ASA: First half 2024 results Thu, Aug 29, 2024 07:00 CET Report this content Oslo, Norway, 29 August 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA gene therapies, today announces... |
04.07.2024 | Breakthrough in Cancer Treatment: SCG Cell Therapy's Next-Generation HPV-Specific TCR T Cell Therapy | SCG Cell Therapy, a biotech company, has received FDA clearance for SCG142, a cutting-edge TCR T cell therapy for HPV-associated solid tumors. This innovative treatment shows promise in revolutionizing cancer care. SCG Cell Therapy's SCG142... |
01.07.2024 | SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors | SINGAPORE, July 1, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (F... |
30.06.2024 | SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors | SINGAPORE, June 30, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (... |
23.05.2024 | Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024 | SUZHOU, China, May 23, 2024 /PRNewswire/ -- On May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal cell carcinoma (R/R mRCC) in an o... |
13.05.2024 | Circio presents pre-clinical proof-of-concept data for its circVec gene therapy platform at the ASGCT 2024 meeting | Circio presents pre-clinical proof-of-concept data for its circVec gene therapy platform at the ASGCT 2024 meeting Mon, May 13, 2024 07:00 CET Report this content Two posters demonstrate in vivo superiority of circular RNA vs. linear mRNA-b... |
10.05.2024 | Toddler born deaf can hear after gene therapy trial breakthrough her parents call "mind-blowing" | London — One of the youngest children in the world to receive a new type of gene therapy to treat genetic deafness can now hear for the first time in her life. The family of the toddler taking part in a medical trial has called the change i... |
06.05.2024 | Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | BOSTON, May 6, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) ... |
23.04.2024 | AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting | April 23, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the publication ... |
17.05.2023 | Skyline Therapeutics Brings Multiple Data Presentations to ASGCT 2023 | SHANGHAI, May 17, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, is showcasing multiple data presen... |
Show more